Goldman Sachs’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,951,297
| Closed | -$24.1M | – | 6510 |
|
|
2024
Q4 | $24.1M | Buy |
1,951,297
+1,475,886
| +310% | +$16.9M | ﹤0.01% | 1932 |
|
|
2024
Q3 | $5.41M | Sell |
475,411
-239,257
| -33% | -$2.4M | ﹤0.01% | 3274 |
|
|
2024
Q2 | $5.1M | Sell |
714,668
-205,433
| -22% | -$1.57M | ﹤0.01% | 3133 |
|
|
2024
Q1 | $6.16M | Buy |
920,101
+283,922
| +45% | +$1.95M | ﹤0.01% | 2901 |
|
|
2023
Q4 | $4.14M | Buy |
636,179
+346,153
| +119% | +$2.23M | ﹤0.01% | 3325 |
|
|
2023
Q3 | $2.74M | Sell |
290,026
-88,345
| -23% | -$1.06M | ﹤0.01% | 3511 |
|
|
2023
Q2 | $5.29M | Sell |
378,371
-36,611
| -9% | -$624K | ﹤0.01% | 3051 |
|
|
2023
Q1 | $7.79M | Sell |
414,982
-34,821
| -8% | -$572K | ﹤0.01% | 2652 |
|
|
2022
Q4 | $6.19M | Buy |
449,803
+55,798
| +14% | +$855K | ﹤0.01% | 2978 |
|
|
2022
Q3 | $7.53M | Buy |
394,005
+44,069
| +13% | +$803K | ﹤0.01% | 2774 |
|
|
2022
Q2 | $5.34M | Sell |
349,936
-65,799
| -16% | -$973K | ﹤0.01% | 3072 |
|
|
2022
Q1 | $8.47M | Sell |
415,735
-116,041
| -22% | -$2.36M | ﹤0.01% | 2850 |
|
|
2021
Q4 | $15.5M | Sell |
531,776
-268,051
| -34% | -$7.67M | ﹤0.01% | 2353 |
|
|
2021
Q3 | $17.3M | Sell |
799,827
-541,450
| -40% | -$13.1M | ﹤0.01% | 2217 |
|
|
2021
Q2 | $34.4M | Buy |
1,341,277
+541,247
| +68% | +$11.6M | 0.01% | 1581 |
|
|
2021
Q1 | $14.6M | Buy |
800,030
+397,484
| +99% | +$6.6M | ﹤0.01% | 2209 |
|
|
2020
Q4 | $4.65M | Buy |
402,546
+256,782
| +176% | +$2.35M | ﹤0.01% | 3058 |
|
|
2020
Q3 | $1.11M | Buy |
145,764
+22,490
| +18% | +$170K | ﹤0.01% | 3996 |
|
|
2020
Q2 | $809K | Buy |
123,274
+17,980
| +17% | +$100K | ﹤0.01% | 4102 |
|
|
2020
Q1 | $538K | Sell |
105,294
-74,154
| -41% | -$449K | ﹤0.01% | 4173 |
|
|
2019
Q4 | $1.38M | Sell |
179,448
-224,351
| -56% | -$1.31M | ﹤0.01% | 3913 |
|
|
2019
Q3 | $2.14M | Buy |
403,799
+384,625
| +2,006% | +$2.39M | ﹤0.01% | 3483 |
|
|
2019
Q2 | $107K | Sell |
19,174
-15,421
| -45% | -$63.6K | ﹤0.01% | 4918 |
|
|
2019
Q1 | $147K | Sell |
34,595
-48,332
| -58% | -$197K | ﹤0.01% | 4865 |
|
|
2018
Q4 | $340K | Buy |
82,927
+33,025
| +66% | +$172K | ﹤0.01% | 4570 |
|
|
2018
Q3 | $342K | Buy |
+49,902
| New | +$296K | ﹤0.01% | 4640 |
|
|
2018
Q2 | – | Sell |
-71,169
| Closed | -$208K | – | 6090 |
|
|
2018
Q1 | $208K | Buy |
71,169
+33,765
| +90% | +$104K | ﹤0.01% | 4986 |
|
|
2017
Q4 | $145K | Buy |
+37,404
| New | +$160K | ﹤0.01% | 5575 |
|
|
2017
Q1 | – | Sell |
-45,515
| Closed | -$98K | – | 7054 |
|
|
2016
Q4 | $98K | Buy |
45,515
+734
| +2% | +$1.72K | ﹤0.01% | 6154 |
|
|
2016
Q3 | $135K | Buy |
44,781
+6,695
| +18% | +$18K | ﹤0.01% | 6073 |
|
|
2016
Q2 | $97K | Buy |
38,086
+20,026
| +111% | +$55.8K | ﹤0.01% | 6144 |
|
|
2016
Q1 | $53K | Buy |
18,060
+9,638
| +114% | +$51.6K | ﹤0.01% | 6402 |
|
|
2015
Q4 | $69K | Buy |
+8,422
| New | +$68K | ﹤0.01% | 6391 |
|
|
2015
Q3 | – | Sell |
-2,777
| Closed | -$25K | – | 7524 |
|
|
2015
Q2 | $25K | Sell |
2,777
-861
| -24% | -$8.28K | ﹤0.01% | 7044 |
|
|
2015
Q1 | $34K | Buy |
3,638
+376
| +12% | +$3.62K | ﹤0.01% | 6803 |
|
|
2014
Q4 | $32K | Buy |
3,262
+800
| +32% | +$8.06K | ﹤0.01% | 6916 |
|
|
2014
Q3 | $23K | Sell |
2,462
-3,090
| -56% | -$34.6K | ﹤0.01% | 6970 |
|
|
2014
Q2 | $73K | Buy |
5,552
+831
| +18% | +$10.5K | ﹤0.01% | 6661 |
|
|
2014
Q1 | $63K | Sell |
4,721
-578
| -11% | -$7.61K | ﹤0.01% | 6509 |
|
|
2013
Q4 | $52K | Buy |
5,299
+2,495
| +89% | +$23.5K | ﹤0.01% | 6416 |
|
|
2013
Q3 | $27K | Sell |
2,804
-56,159
| -95% | -$558K | ﹤0.01% | 6393 |
|
|
2013
Q2 | $532K | Buy |
+58,963
| New | +$618K | ﹤0.01% | 4894 |
|
Other funds holding CDMO
Goldman Sachs's CDMO Position: Q1 2025 in Review
Goldman Sachs sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2025, closing a stake of 1,951,297 shares — an estimated $24.1M sold.
Goldman Sachs first reported a position in CDMO in Q2 2013 and held it in 42 quarters. The position peaked at $34.4M in Q2 2021. 2 funds tracked by Wall St. Rank hold CDMO as of Q1 2025.
- Goldman Sachs reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Goldman Sachs sold 1,951,297 Avid Bioservices, Inc. Common Stock shares in Q1 2025, an estimated $24.1M.
- Goldman Sachs first reported a position in Avid Bioservices, Inc. Common Stock in Q2 2013 and held it in 42 quarters.
- Goldman Sachs's Avid Bioservices, Inc. Common Stock position peaked at $34.4M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2025.
Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.